EffCaMgCit to Prevent Mineral Metabolism and Renal Complications of Chronic PPI Therapy

Summary

Proton pump inhibitors (PPIs) are widely used for the control of gastric ulcer-gastritis, erosive esophagitis (gastroesophageal reflux disease), peptic ulcer disease (duodenal ulcer), and heartburn. Despite their efficacy, their use has been implicated in possibly causing fragility fractures (osteoporosis), hypomagnesemia (magnesium deficiency) and increased risk of chronic kidney disease (CKD). The current trial represents the investigators ongoing effort to discern whether these complications could be averted by effervescent calcium magnesium citrate (EffCaMgCit).

Timeline

Start

2024-04-19

Primary completion

2026-06-25

Completion

2026-06-25

Outcome

Outcome not reported

Stopped (Enrollment): “No enrollment due to COVID”

Drugs

Indications